FindTrial
Sign In

ALVAC-HIV MN120TMG (vCP205)

BIOLOGICAL13 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Walter Reed Army Institute of Research (WRAIR)

Conditions

HIV InfectionsHIV Seronegativity

Phase 1

A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV Vaccine
CompletedNCT00001136
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections, HIV Seronegativity
End: 2001-05-31Updated: 2021-11-01
A Study to Test the Safety of Three Experimental HIV Vaccines
CompletedNCT00000946
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections, HIV Seronegativity
End: 2001-03-31Target: 40Updated: 2021-10-29
HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults
NCT00013572
Walter Reed Army Institute of Research (WRAIR)HIV Infections, HIV Seronegativity
Target: 36Updated: 2005-06-24
A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers
CompletedNCT00000847
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1999-05-31Target: 150Updated: 2021-11-04
Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults
CompletedNCT00000904
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1999-08-31Target: 100Updated: 2021-11-04
A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection
CompletedNCT00004579
Walter Reed Army Institute of Research (WRAIR)HIV Infections, HIV Seronegativity
Start: 1998-04-30Updated: 2005-06-24
A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers
CompletedNCT00001090
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1999-10-31Target: 36Updated: 2021-11-01
Safety and Effectiveness of the Vaccine ALVAC-HIV vCP205 in HIV-Negative Adult Volunteers in Uganda
CompletedNCT00007423
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 2001-09-30Target: 40Updated: 2021-11-01
A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers
CompletedNCT00000879
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections, HIV Seronegativity
End: 2005-04-30Target: 48Updated: 2021-10-29
A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules
CompletedNCT00001076
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1997-12-31Target: 34Updated: 2021-11-04
A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers
CompletedNCT00000884
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 2000-10-31Updated: 2021-10-29
A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) in HIV-1 Uninfected Adult Volunteers
CompletedNCT00001055
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1997-11-30Target: 76Updated: 2021-11-04

Phase 2

A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers
CompletedNCT00000871
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 2000-01-31Target: 420Updated: 2021-11-04

Related Papers

Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene
The Journal of Infectious Diseases2016-02-1119 citations
A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells.
2011-09-169 citations